Mevalonate modulation of cell proliferation and apoptosis

Roberta Baetta, Rodolfo Paoletti, Remo Fumagalli, Maurizio R. Soma

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The effects of a combination of simvastatin, a cholesterol lowering agent, and carmustine (BCNU) on experimental C6 glioma were studied in vitro and in vivo. In vitro simvastatin and BCNU alone inhibited cell proliferation in a dose-dependent fashion. A subliminal concentration of simvastatin (0.1 μM) markedly and synergistically increased the BCNU toxicity to C6 glioma cells. The combination of simvastatin and BCNU resulted predominantly from the profound retardation of cells in the G2-M compartment of the cell cycle. A sub-diploid peak (sub-G1), typical of apoptotic cells, was observed in C6 cells treated for longer time (72 h) with high concentrations of simvastatin (5 μM-up) or BCNU (50 μM-up) as single agents. Interestingly, evidence of apoptotic death was also seen in cells simultaneously exposed to concentrations of the two drugs that, given alone, did not induce signs of DNA damage. In vivo the combination of simvastatin and BCNU caused a synergistic inhibition of the growth of tumors stereotaxically induced in rats, without any significant increase in toxicity. The results provide in vivo support for the combined use of simvastatin and BCNU in brain tumor treatment.

Original languageEnglish
Pages (from-to)257-261
Number of pages5
JournalOncology Reports
Volume4
Issue number1 SUPPL.
Publication statusPublished - 1997

Fingerprint

Carmustine
Mevalonic Acid
Simvastatin
Cell Proliferation
Apoptosis
Glioma
Diploidy
Brain Neoplasms
DNA Damage
Cell Cycle
Cholesterol
Growth

Keywords

  • Apoptosis
  • BCNU
  • Cell cycle
  • Glioma
  • Mevalonate
  • Simvastatin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Baetta, R., Paoletti, R., Fumagalli, R., & Soma, M. R. (1997). Mevalonate modulation of cell proliferation and apoptosis. Oncology Reports, 4(1 SUPPL.), 257-261.

Mevalonate modulation of cell proliferation and apoptosis. / Baetta, Roberta; Paoletti, Rodolfo; Fumagalli, Remo; Soma, Maurizio R.

In: Oncology Reports, Vol. 4, No. 1 SUPPL., 1997, p. 257-261.

Research output: Contribution to journalArticle

Baetta, R, Paoletti, R, Fumagalli, R & Soma, MR 1997, 'Mevalonate modulation of cell proliferation and apoptosis', Oncology Reports, vol. 4, no. 1 SUPPL., pp. 257-261.
Baetta R, Paoletti R, Fumagalli R, Soma MR. Mevalonate modulation of cell proliferation and apoptosis. Oncology Reports. 1997;4(1 SUPPL.):257-261.
Baetta, Roberta ; Paoletti, Rodolfo ; Fumagalli, Remo ; Soma, Maurizio R. / Mevalonate modulation of cell proliferation and apoptosis. In: Oncology Reports. 1997 ; Vol. 4, No. 1 SUPPL. pp. 257-261.
@article{a878f180a5434abd97aa9f58ca9cf98e,
title = "Mevalonate modulation of cell proliferation and apoptosis",
abstract = "The effects of a combination of simvastatin, a cholesterol lowering agent, and carmustine (BCNU) on experimental C6 glioma were studied in vitro and in vivo. In vitro simvastatin and BCNU alone inhibited cell proliferation in a dose-dependent fashion. A subliminal concentration of simvastatin (0.1 μM) markedly and synergistically increased the BCNU toxicity to C6 glioma cells. The combination of simvastatin and BCNU resulted predominantly from the profound retardation of cells in the G2-M compartment of the cell cycle. A sub-diploid peak (sub-G1), typical of apoptotic cells, was observed in C6 cells treated for longer time (72 h) with high concentrations of simvastatin (5 μM-up) or BCNU (50 μM-up) as single agents. Interestingly, evidence of apoptotic death was also seen in cells simultaneously exposed to concentrations of the two drugs that, given alone, did not induce signs of DNA damage. In vivo the combination of simvastatin and BCNU caused a synergistic inhibition of the growth of tumors stereotaxically induced in rats, without any significant increase in toxicity. The results provide in vivo support for the combined use of simvastatin and BCNU in brain tumor treatment.",
keywords = "Apoptosis, BCNU, Cell cycle, Glioma, Mevalonate, Simvastatin",
author = "Roberta Baetta and Rodolfo Paoletti and Remo Fumagalli and Soma, {Maurizio R.}",
year = "1997",
language = "English",
volume = "4",
pages = "257--261",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Mevalonate modulation of cell proliferation and apoptosis

AU - Baetta, Roberta

AU - Paoletti, Rodolfo

AU - Fumagalli, Remo

AU - Soma, Maurizio R.

PY - 1997

Y1 - 1997

N2 - The effects of a combination of simvastatin, a cholesterol lowering agent, and carmustine (BCNU) on experimental C6 glioma were studied in vitro and in vivo. In vitro simvastatin and BCNU alone inhibited cell proliferation in a dose-dependent fashion. A subliminal concentration of simvastatin (0.1 μM) markedly and synergistically increased the BCNU toxicity to C6 glioma cells. The combination of simvastatin and BCNU resulted predominantly from the profound retardation of cells in the G2-M compartment of the cell cycle. A sub-diploid peak (sub-G1), typical of apoptotic cells, was observed in C6 cells treated for longer time (72 h) with high concentrations of simvastatin (5 μM-up) or BCNU (50 μM-up) as single agents. Interestingly, evidence of apoptotic death was also seen in cells simultaneously exposed to concentrations of the two drugs that, given alone, did not induce signs of DNA damage. In vivo the combination of simvastatin and BCNU caused a synergistic inhibition of the growth of tumors stereotaxically induced in rats, without any significant increase in toxicity. The results provide in vivo support for the combined use of simvastatin and BCNU in brain tumor treatment.

AB - The effects of a combination of simvastatin, a cholesterol lowering agent, and carmustine (BCNU) on experimental C6 glioma were studied in vitro and in vivo. In vitro simvastatin and BCNU alone inhibited cell proliferation in a dose-dependent fashion. A subliminal concentration of simvastatin (0.1 μM) markedly and synergistically increased the BCNU toxicity to C6 glioma cells. The combination of simvastatin and BCNU resulted predominantly from the profound retardation of cells in the G2-M compartment of the cell cycle. A sub-diploid peak (sub-G1), typical of apoptotic cells, was observed in C6 cells treated for longer time (72 h) with high concentrations of simvastatin (5 μM-up) or BCNU (50 μM-up) as single agents. Interestingly, evidence of apoptotic death was also seen in cells simultaneously exposed to concentrations of the two drugs that, given alone, did not induce signs of DNA damage. In vivo the combination of simvastatin and BCNU caused a synergistic inhibition of the growth of tumors stereotaxically induced in rats, without any significant increase in toxicity. The results provide in vivo support for the combined use of simvastatin and BCNU in brain tumor treatment.

KW - Apoptosis

KW - BCNU

KW - Cell cycle

KW - Glioma

KW - Mevalonate

KW - Simvastatin

UR - http://www.scopus.com/inward/record.url?scp=0031033680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031033680&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031033680

VL - 4

SP - 257

EP - 261

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1 SUPPL.

ER -